$PODD — BUY 📊

$PODD — BUY 📊 Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. 🎯 Q1 FY26 | Rev $1B | EPS $1.42 vs $1.19 🟢 💡 The market is pricing PODD at a trailing P/E of 35.4x, in line with its historical median, but underestimates the durability of hypergrowth and potential for upward estimate revisions. Consensus modeling a normalization closer to 25% growth, while the company consistently beats and raises guidance. 📉 Reward/Risk: 2.81:1 🏢 Business Quality: 9/10 - Recurring razor-and-blade model, dominant tubeless insulin delivery franchise, high switching costs, strong IP, and expanding TAM with Type 2 and international markets. 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/PODD0620 Also in play: $TNDM $DXCM $ABT $MDT $EW $ROG

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.